FDA OKs Sotatercept, Merck's Pulmonary Arterial Hypertension Drug
Merck is pricing the new drug at $14,000 per vial. The annual cost for most patients eligible for the drug will be approximately $240,000.
The FDA has approved sotatercept, a new treatment for pulmonary arterial hypertension.
Merck is selling the drug under the brand name Winrevair.
Merck is pricing the drug at $14,000 per vial, before any rebates or discounts.
Merck says that approximately two-thirds of patients will need to be treated with a vial every three weeks. At that frequency, the annual cost would add to up approximately $240,000.
Pulmonary arterial hypertension (PAH) is a characterized by high blood pressure in the arteries of the lungs. PAH usually affects women between the ages of 30 and 60, according to the National Organization of Rare Disorders.
Today’s approval came just a day after the FDA approved Opsynvi for PAH. A Johnson & Johnson product, Opsynvi combines macitanten and tadalafil, which are commonly prescribed to treat PAH. Tadalafil is also an erectile dysfunction drug that is sold under the brand name Cialis.
Merck said in a press release today that Winrevair would be available from select specialty pharmacies by the end of next month,
The drug is administered by subcutaneous (under the skin) injection.The Merck press release says it can be administered by patients or caregivers with guidance, training and follow-up from a healthcare provider.
This is a developing story.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
A Motor Neuron Mystery Points to New Potential SMA Treatment Targets
December 20th 2024Some muscles are resistant to the loss of motor neurons seen in patients with spinal muscular atrophy, and new research has discovered that even in muscles that appeared resistant to SMA, subtle changes had occurred at the cellular level.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
